StockMarketWire.com - Data science company Ixico said Monday that it had signed an expanded scope to a current contract with a 'top 10' pharmaceutical company, increasing the value of the contract by £0.6m to £1.6m over the three year term.

The expanded scope would see Ixico providing additional analysis based on advanced imaging modalities in a natural history study of people with early manifestation of Huntington's disease.

As the lead image analysis partner in this study, Ixico would apply its proprietary approaches to data science, together with in-licenced algorithms from leading academic centres, to measure neurological outcomes in study participants.


At 8:33am: [LON:IXI] IXICO plc share price was +0.5p at 33p



Story provided by StockMarketWire.com